Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Agile Therapeutics to join Russell 3000, 2000 indexes » 08:09
06/16/20
06/16
08:09
06/16/20
08:09
AGRX

Agile Therapeutics

$2.86 /

+0.06 (+2.14%)

Agile Therapeutics…

Agile Therapeutics announced that the Company will be added to the Russell 3000 and 2000 Indexes, effective after the U.S. market opens on June 29, 2020, as part of the Russell Indexes annual reconstitution. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell's US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

ShowHide Related Items >><<
AGRX Agile Therapeutics
$2.86 /

+0.06 (+2.14%)

AGRX Agile Therapeutics
$2.86 /

+0.06 (+2.14%)

03/20/20 H.C. Wainwright
H.C. Wainwright 'strongly' reiterates Buy on Agile Therapeutics
02/19/20 Janney Montgomery Scott
Agile Therapeutics price target raised to $9 from $4 at Janney Montgomery Scott
02/18/20 H.C. Wainwright
Agile Therapeutics price target raised to $7 from $5 at H.C. Wainwright
02/18/20 RBC Capital
Agile Therapeutics price target raised to $8 from $5 at RBC Capital
AGRX Agile Therapeutics
$2.86 /

+0.06 (+2.14%)

AGRX Agile Therapeutics
$2.86 /

+0.06 (+2.14%)

AGRX Agile Therapeutics
$2.86 /

+0.06 (+2.14%)

Over a month ago
On The Fly
Fly Intel: After-Hours Movers » 18:56
05/05/20
05/05
18:56
05/05/20
18:56
DIS

Disney

$101.26 /

-1.97 (-1.91%)

, NLS

Nautilus

$6.62 /

+0.53 (+8.70%)

, ANET

Arista Networks

$220.13 /

+9.36 (+4.44%)

, PLNT

Planet Fitness

$56.98 /

-0.44 (-0.77%)

, PRU

Prudential

$58.66 /

-0.14 (-0.24%)

, EA

Electronic Arts

$119.60 /

+2.85 (+2.44%)

, CERS

Cerus

$5.34 /

+0.145 (+2.79%)

, JAZZ

Jazz Pharmaceuticals

$110.63 /

+1.82 (+1.67%)

, AGRX

Agile Therapeutics

$2.85 /

+0.105 (+3.83%)

, NCMI

National CineMedia

$3.03 /

-0.05 (-1.62%)

, MAT

Mattel

$8.60 /

+0.03 (+0.35%)

, PINS

Pinterest

$20.84 /

-0.58 (-2.71%)

, CAMP

CalAmp

$6.47 /

+0.05 (+0.78%)

, SPCE

Virgin Galactic

$16.65 /

-0.05 (-0.30%)

, DVA

DaVita

$78.83 /

+3.69 (+4.91%)

, OXY

Occidental Petroleum

$15.28 /

-0.25 (-1.61%)

, BGS

B&G Foods

$19.55 /

-0.18 (-0.91%)

, STOR

Store Capital

$18.21 /

-0.015 (-0.08%)

, BYND

Beyond Meat

$100.14 /

+5.02 (+5.28%)

, ATVI

Activision Blizzard

$68.53 /

+1.85 (+2.77%)

, DVN

Devon Energy

$11.17 /

-0.25 (-2.19%)

, OSPN

OneSpan

$16.43 /

+0.22 (+1.36%)

, RSG

Republic Services

$77.40 /

+0.17 (+0.22%)

, CC

Chemours

$12.17 /

+1.24 (+11.34%)

, AXNX

Axonics

$32.48 /

+1.23 (+3.94%)

, CLVS

Clovis

$7.76 /

-0.29 (-3.60%)

, LPSN

LivePerson

$23.39 /

+0.48 (+2.10%)

, VAPO

Vapotherm

$22.41 /

+1.5 (+7.17%)

, MELI

MercadoLibre

$620.48 /

+12.95 (+2.13%)

, MED

Medifast

$75.62 /

+2.7 (+3.70%)

, AOSL

Alpha & Omega

$11.17 /

+0.165 (+1.50%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
DIS Disney
$101.26 /

-1.97 (-1.91%)

05/06/20 JPMorgan
Disney opening in Shanghai first of many catalysts, says JPMorgan
05/06/20 Morgan Stanley
Morgan Stanley highlights three Disney 'unknowns that remain largely unknown'
05/06/20 BMO Capital
Disney price target lowered to $140 from $150 at BMO Capital
05/04/20
Fly Intel: Top five analyst downgrades
NLS Nautilus
$6.62 /

+0.53 (+8.70%)

05/06/20 Lake Street
Nautilus price target raised to $9 from $7 at Lake Street
04/23/20
Nautilus upgraded to Buy at SunTrust on expected home fitness surge
04/23/20 SunTrust
Nautilus upgraded to Buy from Hold at SunTrust
04/13/20 Lake Street
Nautilus' new products seeing strong consumer interest, says Lake Street
ANET Arista Networks
$220.13 /

+9.36 (+4.44%)

05/06/20 Nomura Instinet
Arista Networks price target raised to $190 from $180 at Nomura Instinet
04/09/20 Piper Sandler
Arista Networks downgraded to Neutral from Overweight at Piper Sandler
03/16/20 Citi
Arista Networks price target lowered to $200 from $225 at Citi
03/13/20 Nomura Instinet
Arista Networks price target lowered to $180 from $190 at Nomura Instinet
PLNT Planet Fitness
$56.98 /

-0.44 (-0.77%)

05/06/20 Wedbush
Planet Fitness price target lowered to $55 from $65 at Wedbush
05/06/20 DA Davidson
Planet Fitness price target raised to $70 from $60 at DA Davidson
05/06/20 Cowen
Planet Fitness price target raised to $65 from $50 at Cowen
05/06/20 Guggenheim
Planet Fitness price target lowered to $75 from $85 at Guggenheim
PRU Prudential
$58.66 /

-0.14 (-0.24%)

03/20/20 RBC Capital
RBC Capital sees some time before Life Insurance returns to 'normal'
03/20/20 RBC Capital
Prudential downgraded to Sector Perform from Outperform at RBC Capital
03/11/20 B. Riley FBR
B. Riley FBR downgrades CNO Financial, Progressive to Neutral from Buy
01/02/20 JPMorgan
JPMorgan cautious on life insurance sector in 2020
EA Electronic Arts
$119.60 /

+2.85 (+2.44%)

05/06/20 Needham
Electronic Arts price target raised to $135 from $120 at Needham
05/06/20 Wedbush
Electronic Arts price target raised to $145 from $135 at Wedbush
05/06/20 Cowen
Electronic Arts price target raised to $129 from $119 at Cowen
05/06/20 Jefferies
Jefferies recommends investors stick with Activision Blizzard over EA
CERS Cerus
$5.34 /

+0.145 (+2.79%)

02/26/20 BTIG
Cerus initiated with a Buy at BTIG
01/23/20 Cowen
Cowen encouraged by Cerus data on Intercept in light of new coronavirus
11/13/19 BTIG
Cerus upgraded to Buy from Neutral at BTIG
08/28/19
Fly Intel: Top five analyst initiations
JAZZ Jazz Pharmaceuticals
$110.63 /

+1.82 (+1.67%)

05/06/20 SVB Leerink
Jazz Pharmaceuticals price target lowered to $160 from $169 at SVB Leerink
05/06/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $132 from $141 at Oppenheimer
05/06/20 BMO Capital
Jazz Pharmaceuticals price target lowered to $193 from $205 at BMO Capital
05/06/20 Piper Sandler
Jazz Pharmaceuticals price target lowered to $113 from $127 at Piper Sandler
AGRX Agile Therapeutics
$2.85 /

+0.105 (+3.83%)

03/20/20 H.C. Wainwright
H.C. Wainwright 'strongly' reiterates Buy on Agile Therapeutics
02/19/20 Janney Montgomery Scott
Agile Therapeutics price target raised to $9 from $4 at Janney Montgomery Scott
02/18/20 H.C. Wainwright
Agile Therapeutics price target raised to $7 from $5 at H.C. Wainwright
02/18/20 RBC Capital
Agile Therapeutics price target raised to $8 from $5 at RBC Capital
NCMI National CineMedia
$3.03 /

-0.05 (-1.62%)

05/04/20 Wedbush
National CineMedia price target lowered to $4.50 from $10 at Wedbush
04/17/20 B. Riley FBR
White House guidelines give some clarity to film exhibitors, says B. Riley FBR
03/18/20 Benchmark
Benchmark cuts National CineMedia to Hold as Universal goes to home with Trolls
03/18/20 Barrington
National CineMedia downgraded to Market Perform from Outperform at Barrington
MAT Mattel
$8.60 /

+0.03 (+0.35%)

05/01/20 JPMorgan
JPMorgan lowers Mattel target to $11, removed from Analyst Focus List
04/21/20 Goldman Sachs
Mattel price target lowered to $10 from $14 at Goldman Sachs
04/17/20 Wolfe Research
Mattel initiated with an Outperform at Wolfe Research
04/16/20 Berenberg
Mattel initiated with a Hold at Berenberg
PINS Pinterest
$20.84 /

-0.58 (-2.71%)

05/06/20 DA Davidson
Pinterest downgraded to Neutral from Buy at DA Davidson
05/06/20 Baird
Pinterest price target lowered to $20 from $23 at Baird
05/06/20 DA Davidson
Pinterest downgraded to Neutral from Buy at DA Davidson
05/06/20 Nomura Instinet
Pinterest price target lowered to $28 from $32 at Nomura Instinet
CAMP CalAmp
$6.47 /

+0.05 (+0.78%)

04/17/20 Jefferies
CalAmp upgraded to Buy at Jefferies with downside case seen as priced in
04/17/20 Jefferies
CalAmp upgraded to Buy from Hold at Jefferies
03/26/20 JPMorgan
CalAmp price target lowered to $9 from $12 at JPMorgan
03/06/20 Canaccord
CalAmp price target lowered to $12 from $17 at Canaccord
SPCE Virgin Galactic
$16.65 /

-0.05 (-0.30%)

03/24/20 Morgan Stanley
Morgan Stanley upgrades Virgin Galactic to Overweight after over 70% drop
03/24/20 Morgan Stanley
Virgin Galactic upgraded to Overweight from Equal Weight at Morgan Stanley
03/03/20 Morgan Stanley
Lead up to next lunar landings can have 'powerful impact,' says Morgan Stanley
02/27/20
Fly Intel: Top five analyst downgrades
DVA DaVita
$78.83 /

+3.69 (+4.91%)

02/11/20 SunTrust
DaVita price target raised to $90 from $80 at SunTrust
01/24/20
Fly Intel: Top five analyst upgrades
01/24/20 Goldman Sachs
DaVita upgraded to Buy from Neutral at Goldman Sachs
12/20/19 JPMorgan
JPMorgan reverses stance on Managed Care, turns more bullish into 2020
OXY Occidental Petroleum
$15.28 /

-0.25 (-1.61%)

05/05/20 Mizuho
Western Midstream price target lowered to $12 from $23 at Mizuho
05/04/20 Tudor Pickering
Occidental Petroleum downgraded to Sell from Hold at Tudor Pickering
04/03/20 Mizuho
Occidental Petroleum downgraded to Neutral from Buy at Mizuho
04/01/20 KeyBanc
KeyBanc expects neutral stock reaction to Occidental's SVP of strategy departure
BGS B&G Foods
$19.55 /

-0.18 (-0.91%)

04/28/20 Credit Suisse
B&G Foods upgraded to Neutral from Underperform at Credit Suisse
04/20/20 Evercore ISI
General Mills, B&G Foods added to Tactical Outperform List at Evercore ISI
02/27/20 BMO Capital
B&G Foods price target lowered to $16 from $20 at BMO Capital
01/22/20 Jefferies
B&G Foods initiated with a Hold at Jefferies
STOR Store Capital
$18.21 /

-0.015 (-0.08%)

05/04/20 Morgan Stanley
Morgan Stanley shakes up REIT ratings with Realty Income upgrade, two downgrades
05/04/20 Morgan Stanley
Store Capital downgraded to Equal Weight from Overweight at Morgan Stanley
04/24/20 Mizuho
Store Capital downgraded to Neutral from Buy at Mizuho
04/20/20 BMO Capital
Store Capital downgraded to Market Perform from Outperform at BMO Capital
BYND Beyond Meat
$100.14 /

+5.02 (+5.28%)

05/06/20 Goldman Sachs
Goldman Sachs reduces 2020-22 revenue estimates for Beyond Meat after Q1 report
05/06/20 DA Davidson
Beyond Meat price target raised to $83 from $62 at DA Davidson
05/06/20 Barclays
Beyond Meat reported strong Q1 results, says Barclays
05/01/20
Fly Intel: Top five analyst downgrades
ATVI Activision Blizzard
$68.53 /

+1.85 (+2.77%)

05/06/20 Wedbush
Activision Blizzard price target raised to $84 from $76 at Wedbush
05/06/20 Oppenheimer
Activision Blizzard price target raised to $73 from $68 at Oppenheimer
05/06/20 Cowen
Activision Blizzard price target raised to $66 from $60 at Cowen
DVN Devon Energy
$11.17 /

-0.25 (-2.19%)

05/06/20 Susquehanna
Devon Energy price target raised to $13 from $12 at Susquehanna
03/25/20 Piper Sandler
Devon Energy downgraded to Neutral from Overweight at Piper Sandler
03/24/20 Piper Sandler
Devon Energy downgraded to Neutral from Overweight at Piper Sandler
03/24/20 SunTrust
Devon Energy price target lowered to $8 from $15 at SunTrust
OSPN OneSpan
$16.43 /

+0.22 (+1.36%)

03/27/20 BTIG
OneSpan assumed with a Neutral at BTIG
06/25/19 B. Riley FBR
OneSpan initiated with a Buy at B. Riley FBR
05/31/19 Wedbush
OneSpan initiated with a Neutral at Wedbush
RSG Republic Services
$77.40 /

+0.17 (+0.22%)

04/14/20 Jefferies
Jefferies downgrades Republic Services after commercial waste survey
04/14/20 Jefferies
Republic Services downgraded to Hold from Buy at Jefferies
03/31/20 BMO Capital
Republic Services price target lowered to $87 from $108 at BMO Capital
03/30/20 JPMorgan
JPMorgan says solid waste should be core holding, upgrades Republic Services
CC Chemours
$12.17 /

+1.24 (+11.34%)

04/14/20 Susquehanna
Chemours price target lowered to $17 from $23 at Susquehanna
03/31/20 Deutsche Bank
Dismissed Chemours suit 'major victory' for DuPont, says Deutsche Bank
03/26/20 BMO Capital
Chemours price target lowered to $21 from $33 at BMO Capital
03/25/20 SunTrust
Chemours price target lowered to $10 from $19 at SunTrust
AXNX Axonics
$32.48 /

+1.23 (+3.94%)

04/21/20 Piper Sandler
Axonics price target lowered to $44 from $48 at Piper Sandler
04/14/20 Piper Sandler
Axonics next-gen INS not compatible with InterStim II leads, says Piper Sandler
04/08/20 Wells Fargo
Axonics price target lowered to $35 from $47 at Wells Fargo
03/05/20 SunTrust
Axonics price target raised to $48 from $38 at SunTrust
CLVS Clovis
$7.76 /

-0.29 (-3.60%)

05/06/20 H.C. Wainwright
Clovis price target raised to $29 from $27 at H.C. Wainwright
05/06/20 Piper Sandler
Clovis price target raised to $6 from $5.25 at Piper Sandler
04/27/20 SVB Leerink
Clovis downgraded to Underperform at SVB Leerink as prostate opportunity fades
04/27/20 SVB Leerink
Clovis downgraded to Underperform from Market Perform at SVB Leerink
LPSN LivePerson
$23.39 /

+0.48 (+2.10%)

05/06/20 B. Riley FBR
LivePerson price target raised to $36 from $31 at B. Riley FBR
05/06/20 KeyBanc
LivePerson price target lowered to $38 from $43 at KeyBanc
05/06/20 Mizuho
LivePerson price target raised to $40 from $30 at Mizuho
05/06/20 Jefferies
LivePerson price target raised to $33 from $27 at Jefferies
VAPO Vapotherm
$22.41 /

+1.5 (+7.17%)

04/14/20 Canaccord
Vapotherm price target raised to $20 from $14 at Canaccord
03/05/20 Canaccord
Vapotherm remains top 2020 turnaround pick, says Canaccord
06/05/19 Canaccord
Vapotherm remains a top small-cap pick, says Canaccord
MELI MercadoLibre
$620.48 /

+12.95 (+2.13%)

05/06/20 Credit Suisse
MercadoLibre price target raised to $770 from $720 at Credit Suisse
05/06/20 Citi
MercadoLibre upgraded to Buy from Neutral at Citi
05/06/20 Barclays
MercadoLibre price target raised to $810 from $620 at Barclays
05/06/20 Stifel
MercadoLibre price target raised to $750 from $655 at Stifel
MED Medifast
$75.62 /

+2.7 (+3.70%)

02/27/20 DA Davidson
Medifast price target raised to $83 from $74 at DA Davidson
02/27/20 Jefferies
Medifast downgraded to Hold from Buy at Jefferies
01/14/20 Jefferies
Medifast price target raised to $130 from $110 at Jefferies
12/20/19 Jefferies
Potential activist-led bid for Medifast reinforces value gap, says Jefferies
AOSL Alpha & Omega
$11.17 /

+0.165 (+1.50%)

03/19/20 B. Riley FBR
B. Riley FBR downgrades 10 Semiconductor names on escalating risks
03/19/20 B. Riley FBR
Alpha & Omega downgraded to Neutral from Buy at B. Riley FBR
09/17/19 Loop Capital
Alpha & Omega growth trajectory encouraging, says Loop Capital
08/22/19 Loop Capital
Alpha & Omega price target raised to $18 from $13 at Loop Capital
Hot Stocks
Agile Therapeutics updates Twirla commercialization plans » 16:13
05/05/20
05/05
16:13
05/05/20
16:13
AGRX

Agile Therapeutics

$2.73 /

-0.015 (-0.55%)

The Company has completed…

The Company has completed production of the planned manufacturing pre-validation batch of Twirla and subject to completion of the final quality assurance testing, the Company expects to begin manufacture of the validation batches of Twirla(R) over the next four months. The Company expects these validation batches, if successful, will be available for commercial launch in the fourth quarter of 2020. At the same time, the Company will continue to prepare for the availability of commercial product supply. The Company has initiated work with managed care and patient payors to gain market access for Twirla. In the second quarter of 2020, the Company plans to begin hiring and training an initial sales team, which it estimates to be in the range of 70 to 100 persons. The Company intends to begin to ship product to wholesalers in the fourth quarter of 2020.

ShowHide Related Items >><<
AGRX Agile Therapeutics
$2.73 /

-0.015 (-0.55%)

03/20/20 H.C. Wainwright
H.C. Wainwright 'strongly' reiterates Buy on Agile Therapeutics
02/19/20 Janney Montgomery Scott
Agile Therapeutics price target raised to $9 from $4 at Janney Montgomery Scott
02/18/20 H.C. Wainwright
Agile Therapeutics price target raised to $7 from $5 at H.C. Wainwright
02/18/20 RBC Capital
Agile Therapeutics price target raised to $8 from $5 at RBC Capital
Earnings
Agile Therapeutics sees FY20 operating expenses $52M-$56M » 16:11
05/05/20
05/05
16:11
05/05/20
16:11
AGRX

Agile Therapeutics

$2.81 /

+0.065 (+2.37%)

Moving forward, the…

Moving forward, the Company plans to monitor spending closely. The Company expects operating expenses for the full year 2020 to be in the range of $52.0 million to $56.0 million, with general and administrative expenses accounting for approximately 70% of the spending as it builds out its commercial infrastructure. Net revenue in the fourth quarter of 2020, reflecting the initial launch of Twirla, is expected to be in the range of $4.0 million to $6.0 million. Based on the Company's current business plan and ability to get Twirla launched, the Company believes that its cash and cash equivalents as of March 31, 2020 will be sufficient to meet its projected operating requirements through the end of 2021. If the COVID-19 outbreak or other factors impact the Company's business plan or its ability to generate revenue from the launch of Twirla, the Company believes it has the ability to revise its commercial plans, including curtailing sales and marketing spending, to allow it to continue to fund its operations.

ShowHide Related Items >><<
AGRX Agile Therapeutics
$2.81 /

+0.065 (+2.37%)

03/20/20 H.C. Wainwright
H.C. Wainwright 'strongly' reiterates Buy on Agile Therapeutics
02/19/20 Janney Montgomery Scott
Agile Therapeutics price target raised to $9 from $4 at Janney Montgomery Scott
02/18/20 H.C. Wainwright
Agile Therapeutics price target raised to $7 from $5 at H.C. Wainwright
02/18/20 RBC Capital
Agile Therapeutics price target raised to $8 from $5 at RBC Capital
Earnings
Agile Therapeutics reports Q1 EPS (10c), consensus (9c) » 16:06
05/05/20
05/05
16:06
05/05/20
16:06
AGRX

Agile Therapeutics

$2.90 /

+0.15 (+5.46%)

As of March 31, Agile had…

As of March 31, Agile had $93.9M of cash and cash equivalents compared to $34.5M of cash and cash equivalents as of December 31, 2019. The company said, "Moving forward, the Company plans to monitor spending closely. The Company expects operating expenses for the full year 2020 to be in the range of $52.0 million to $56.0 million, with general and administrative expenses accounting for approximately 70% of the spending as it builds out its commercial infrastructure. Net revenue in the fourth quarter of 2020, reflecting the initial launch of Twirla, is expected to be in the range of $4.0 million to $6.0 million. Based on the Company's current business plan and ability to get Twirla launched, the Company believes that its cash and cash equivalents as of March 31, 2020 will be sufficient to meet its projected operating requirements through the end of 2021. If the COVID-19 outbreak or other factors impact the Company's business plan or its ability to generate revenue from the launch of Twirla, the Company believes it has the ability to revise its commercial plans, including curtailing sales and marketing spending, to allow it to continue to fund its operations."

ShowHide Related Items >><<
AGRX Agile Therapeutics
$2.90 /

+0.15 (+5.46%)

03/20/20 H.C. Wainwright
H.C. Wainwright 'strongly' reiterates Buy on Agile Therapeutics
02/19/20 Janney Montgomery Scott
Agile Therapeutics price target raised to $9 from $4 at Janney Montgomery Scott
02/18/20 H.C. Wainwright
Agile Therapeutics price target raised to $7 from $5 at H.C. Wainwright
02/18/20 RBC Capital
Agile Therapeutics price target raised to $8 from $5 at RBC Capital
Earnings
Agile Therapeutics reports Q1 EPS (10c), consensus (9c) » 16:06
05/05/20
05/05
16:06
05/05/20
16:06
AGRX

Agile Therapeutics

$2.90 /

+0.15 (+5.46%)

In February 2020, the…

In February 2020, the Company entered into a credit agreement with Perceptive Advisors for a senior secured term loan facility of up to $35 million. A first tranche of $5 million was funded on execution of the credit agreement. A second tranche of $15 million was funded as a result of the approval of Twirla by the FDA. Another $15 million tranche will be available upon the achievement of certain revenue milestones. The Company is permitted to make interest-only payments on the loan until February 2023. In addition, the Company issued Perceptive warrants to purchase 1,400,000 shares of Agile common stock. As of March 31, 2020, Agile had $93.9 million of cash and cash equivalents compared to $34.5 million of cash and cash equivalents as of December 31, 2019.

ShowHide Related Items >><<
AGRX Agile Therapeutics
$2.90 /

+0.15 (+5.46%)

03/20/20 H.C. Wainwright
H.C. Wainwright 'strongly' reiterates Buy on Agile Therapeutics
02/19/20 Janney Montgomery Scott
Agile Therapeutics price target raised to $9 from $4 at Janney Montgomery Scott
02/18/20 H.C. Wainwright
Agile Therapeutics price target raised to $7 from $5 at H.C. Wainwright
02/18/20 RBC Capital
Agile Therapeutics price target raised to $8 from $5 at RBC Capital
Hot Stocks
Agile Therapeutics nominates Sharon Barbari to board of directors » 08:27
04/22/20
04/22
08:27
04/22/20
08:27
AGRX

Agile Therapeutics

$2.09 /

-0.085 (-3.91%)

, CYTK

Cytokinetics

$15.00 /

-0.5 (-3.23%)

, GILD

Gilead

$78.48 /

-2.76 (-3.40%)

Agile Therapeutics (AGRX)…

Agile Therapeutics (AGRX) announced that the company has nominated Sharon Barbari for election as a class III director to replace Abhijeet Lele, a member of the company's board of directors and the board's Lead Independent Director, who will not stand for re-election and cease to be a director on June 9, 2020, the date of the company's Annual Meeting of Stockholders. In addition, William McKee has informed the company that he will retire from the company's board of directors effective June 9, 2020. The company plans to appoint Sandra Carson, M.D., FACOG as a class II director to replace Mr. McKee when he retires Barbari has over 40 years of pharmaceutical and biotechnology experience, having served in various senior financial roles, including CFO, at several companies during her career, including Cytokinetics (CYTK), InterMune and Gilead Sciences (GILD). Carson is a Professor of Obstetrics, Gynecology and Reproductive Sciences and Director, Reproductive Endocrinology and Infertility at Yale University. Most recently, she served as the Emeritus Vice President for Education at the American College of Obstetricians & Gynecologists from August 2018 to February 2019 and Vice President for Education from March 2013 to August 2018. The company's board of directors plans to appoint Seth H.Z. Fischer as the lead independent director to replace Mr. Lele at the annual meeting of stockholders on June 9, 2020.

ShowHide Related Items >><<
AGRX Agile Therapeutics
$2.09 /

-0.085 (-3.91%)

03/20/20 H.C. Wainwright
H.C. Wainwright 'strongly' reiterates Buy on Agile Therapeutics
02/19/20 Janney Montgomery Scott
Agile Therapeutics price target raised to $9 from $4 at Janney Montgomery Scott
02/18/20 H.C. Wainwright
Agile Therapeutics price target raised to $7 from $5 at H.C. Wainwright
02/18/20 RBC Capital
Agile Therapeutics price target raised to $8 from $5 at RBC Capital
CYTK Cytokinetics
$15.00 /

-0.5 (-3.23%)

04/17/20 Cantor Fitzgerald
Cytokinetics price target raised to $23 from $12 at Cantor Fitzgerald
04/09/20 Morgan Stanley
Cytokinetics upgraded to Overweight ahead of 'crucial year' at Morgan Stanley
04/09/20 Morgan Stanley
Cytokinetics upgraded to Overweight from Equal Weight at Morgan Stanley
03/04/20 H.C. Wainwright
H.C. Wainwright goes 'all in' on Cytokinetics into 'transformational' 2020
GILD Gilead
$78.48 /

-2.76 (-3.40%)

04/20/20
Fly Intel: Top five analyst downgrades
04/20/20 Wells Fargo
Gilead fully-valued at present, says Wells Fargo in downgrade to Equal Weight
04/20/20 BMO Capital
Gilead downgraded to Market Perform from Outperform at BMO Capital
04/20/20 Wells Fargo
Gilead downgraded to Equal Weight from Overweight at Wells Fargo
Over a quarter ago
Recommendations
H.C. Wainwright 'strongly' reiterates Buy on Agile Therapeutics » 07:14
03/20/20
03/20
07:14
03/20/20
07:14
AGRX

Agile Therapeutics

$1.62 /

-0.04 (-2.41%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Oren Livnat "strongly" reiterates a Buy rating on Agile Therapeutics with a $6 price target. The analyst says the company is "well capitalized and underappreciated." The recent share selloff is overdone as the company is well positioned to "weather storm and come out the other side launching," Livnat tells investors in a research note.

ShowHide Related Items >><<
AGRX Agile Therapeutics
$1.62 /

-0.04 (-2.41%)

02/19/20 Janney Montgomery Scott
Agile Therapeutics price target raised to $9 from $4 at Janney Montgomery Scott
02/18/20 H.C. Wainwright
Agile Therapeutics price target raised to $7 from $5 at H.C. Wainwright
02/18/20 RBC Capital
Agile Therapeutics price target raised to $8 from $5 at RBC Capital
11/15/19 William Blair
William Blair still thinks Agile likely to get approval for Twirla despite delay
Hot Stocks
Fly Intel: Pre-market Movers » 09:00
02/21/20
02/21
09:00
02/21/20
09:00
S

Sprint

$9.52 /

+0.02 (+0.21%)

, TMUS

T-Mobile

$99.51 /

-0.96 (-0.96%)

, CHWY

Chewy

$29.28 /

+0.01 (+0.03%)

, DE

Deere

$165.80 /

+0.885 (+0.54%)

, DBX

Dropbox

$18.70 /

+0.39 (+2.13%)

, SFM

Sprouts Farmers Market

$16.05 /

+0.185 (+1.17%)

, CNK

Cinemark

$32.69 /

+0.58 (+1.81%)

, FSLR

First Solar

$59.31 /

+1.98 (+3.45%)

, TRUE

TrueCar

$3.94 /

+0.14 (+3.68%)

, ZS

Zscaler

$65.23 /

-0.01 (-0.02%)

, AGRX

Agile Therapeutics

$3.57 /

-0.08 (-2.19%)

, BXC

BlueLinx

$19.50 /

+5.575 (+40.04%)

HIGHER: Sprint (S), up 6%…

HIGHER: Sprint (S), up 6% after modifying the T-Mobile (TMUS) combination agreement and announcing the deal could close as early as April 1... Chewy (CHWY), up 4% after RBC Capital analyst Mark Mahaney upgraded shares to Outperform from Sector Perform with an unchanged $38 price target. The analyst sees FY20 as a profitability inflection year for the company and believes that the stock offers a "highly favorable" risk-reward. UP AFTER EARNINGS: Deere (DE), up 6%... Dropbox (DBX), up 15%... Sprouts Farmers Market (SFM), up 9%. DOWN AFTER EARNINGS: Cinemark (CNK), down 5%... First Solar (FSLR), down 10%... TrueCar (TRUE), down 28%... Zscaler (ZS), down 13%. ALSO LOWER: T-Mobile, down 1% after Raymond James analyst Ric Prentiss downgraded the stock to Outperform from Strong Buy with a price target of $107, up from $99... Agile Therapeutics (AGRX), down 13% after its 15M share spot secondary offering priced at $3.00 per share... BlueLinx Holdings (BXC), down 28% after the company responded to a press release issued by an investment firm that goes by the name of Bluefin Acquisitions, which claimed that it was making a tender offer to acquire at least 35% of the company's common stock at a price of $24.50 per share. "The company was not aware of this purported offer," BlueLinx stated in its response last night after the market close.

ShowHide Related Items >><<
S Sprint
$9.52 /

+0.02 (+0.21%)

02/21/20 Raymond James
Raymond James downgrades T-Mobile to Outperform ahead of Sprint integration
02/21/20 Pivotal Research
Dish price target raised to $39 from $37 at Pivotal Research
02/13/20 HSBC
SoftBank price target raised to 7,000 yen after Sprint deal approval
02/12/20 Argus
T-Mobile price target raised to $105 from $93 at Argus
TMUS T-Mobile
$99.51 /

-0.96 (-0.96%)

02/21/20 Raymond James
T-Mobile downgraded to Outperform from Strong Buy at Raymond James
CHWY Chewy
$29.28 /

+0.01 (+0.03%)

02/21/20 RBC Capital
Chewy upgraded to Outperform from Sector Perform at RBC Capital
01/27/20 Wedbush
Chewy upgraded to Outperform at Wedbush on online pet industry sales growth
01/27/20 Wedbush
Chewy upgraded to Outperform from Neutral at Wedbush
12/10/19 JPMorgan
Chewy shares down on tomorrow's IPO lockup, says JPMorgan
DE Deere
$165.80 /

+0.885 (+0.54%)

02/10/20 Deutsche Bank
CNH Industrial upgraded to Buy from Hold at Deutsche Bank
01/17/20 Stephens
Expectation of 2020 farmer bailouts in 'embedded in Deere shares,' says Stephens
01/14/20 Wells Fargo
Deere price target raised to $185 from $177 at Wells Fargo
01/10/20 BMO Capital
BMO says Deere investors 'missing' companys leading position in precision ag
DBX Dropbox
$18.70 /

+0.39 (+2.13%)

02/21/20 Canaccord
Dropbox results solid but momentum hard to break, says Canaccord
02/21/20 Deutsche Bank
Dropbox target raised to $30 on 'thesis-changing' Q4 at Deutsche Bank
02/21/20 Jefferies
Dropbox price target raised to $21 from $19 at Jefferies
01/10/20
Fly Intel: Top five analyst downgrades
SFM Sprouts Farmers Market
$16.05 /

+0.185 (+1.17%)

02/21/20 Bernstein
Bernstein upgrades Sprouts Farmers Market to Outperform after selloff
02/21/20 Bernstein
Sprouts Farmers Market upgraded to Outperform from Market Perform at Bernstein
02/11/20 Gordon Haskett
Sprouts Farmers Market upgraded to Hold from Reduce at Gordon Haskett
01/30/20 UBS
Sprouts Farmers Market downgraded to Neutral from Buy at UBS
CNK Cinemark
$32.69 /

+0.58 (+1.81%)

02/12/20 MKM Partners
Cinemark price target lowered to $36 from $42 at MKM Partners
02/03/20 Wedbush
Cinemark price target lowered to $40 from $45 at Wedbush
01/03/20 Loop Capital
Cinemark price target lowered to $42 from $48 at Loop Capital
11/22/19
Fly Intel: Top five analyst downgrades
FSLR First Solar
$59.31 /

+1.98 (+3.45%)

02/21/20 JPMorgan
First Solar Q4 weak, but overall trajectory encouraging, says JPMorgan
02/21/20 Cowen
First Solar price targetlowered to $76 from $83 at Cowen
01/22/20 JPMorgan
JPMorgan constructive on Alternative Energy fundamentals into Q4 esults
01/15/20
Fly Intel: Top five analyst downgrades
TRUE TrueCar
$3.94 /

+0.14 (+3.68%)

02/21/20 Stephens
TrueCar loss of USAA likely to drives shares toward $2, says Stephens
09/12/19
Fly Intel: Top five analyst initiations
09/11/19 Needham
TrueCar initiated with a Hold at Needham
09/11/19 Needham
TrueCar initiated with a Hold at Needham
ZS Zscaler
$65.23 /

-0.01 (-0.02%)

02/21/20 Cowen
Zscaler weakness a buying opportunity, says Cowen
02/21/20 Rosenblatt
Zscaler price target raised to $58 from $50 at Rosenblatt
02/13/20 OTR Global
Zscaler upgraded to Mixed from Negative at OTR Global
12/30/19 Needham
Needham adds Crowdstrike to Conviction List, sees correction as opportunity
AGRX Agile Therapeutics
$3.57 /

-0.08 (-2.19%)

02/19/20 Janney Montgomery Scott
Agile Therapeutics price target raised to $9 from $4 at Janney Montgomery Scott
02/18/20 H.C. Wainwright
Agile Therapeutics price target raised to $7 from $5 at H.C. Wainwright
02/18/20 RBC Capital
Agile Therapeutics price target raised to $8 from $5 at RBC Capital
11/15/19 William Blair
William Blair still thinks Agile likely to get approval for Twirla despite delay
BXC BlueLinx
$19.50 /

+5.575 (+40.04%)

02/04/20 B. Riley FBR
BlueLinx price target lowered to $17 from $25 at B. Riley FBR
11/25/19 B. Riley FBR
BlueLinx selloff on shelf registration overdone, says B. Riley FBR
08/08/19
Fly Intel: Top analyst initiations
08/07/19 B. Riley FBR
BlueLinx initiated with a Buy at B. Riley FBR
  • 21
    Feb
Syndicate
Agile Therapeutics 15M share Spot Secondary priced at $3.00 » 08:38
02/21/20
02/21
08:38
02/21/20
08:38
AGRX

Agile Therapeutics

$3.57 /

-0.08 (-2.19%)

RBC Capital, William…

RBC Capital, William Blair and Oppenheimer acted as joint book running managers for the offering.

ShowHide Related Items >><<
AGRX Agile Therapeutics
$3.57 /

-0.08 (-2.19%)

02/19/20 Janney Montgomery Scott
Agile Therapeutics price target raised to $9 from $4 at Janney Montgomery Scott
02/18/20 H.C. Wainwright
Agile Therapeutics price target raised to $7 from $5 at H.C. Wainwright
02/18/20 RBC Capital
Agile Therapeutics price target raised to $8 from $5 at RBC Capital
11/15/19 William Blair
William Blair still thinks Agile likely to get approval for Twirla despite delay
  • 21
    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.